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established best practice.6–7 It departs from previously
suggested phrasing that the research should be of
“direct benefit to persons with that particular
condition,” which would have precluded much
observational or epidemiological research. One
residual point is that the new bill restricts research to
that which examines the causes or treatment of “a con-
dition attributable to the impairment [or disturbance]
of the mind or brain.” This may preclude research in
intensive care units where the subject is incompetent
not due to neurological disease, but instead due to
sedative therapy which is essential to their care. One
solution would be to recognise that essential therapy is
part of the overall burden of disease, and permit
research into the underlying illness when such therapy
compromises competence. It is also important that the
mental capacity bill is interpreted to recognise
explicitly that it is ethical to proceed when clinical
equipoise exists. Clear and enabling guidance notes, or
appropriate amendments, are therefore necessary.
Some ground has also been achieved in the human
tissue bill since an earlier draft of this editorial was
shared with Department of Health officials. New
amendments have just been announced that allow the
secretary of state to specify conditions under which
consent can be presumed for research involving tissue
from an incompetent person.8 These conditions have
not been itemised. It is to be hoped they will interact
simply and clearly with the conditions in the revised
mental capacity bill. The secretary will also be given
power to set conditions allowing analysis of an incom-
petent person’s DNA. This should alleviate the
problem in earlier versions of the human tissue bill
which, ignoring the Human Genetics Commission’s
2002 recommendation,9 did not allow DNA to be ana-
lysed for the benefit of a family member (for example,
to predict the risk of breast cancer). These improve-
ments to the human tissue bill will not be realised until
regulations are drafted and approved by parliament. It
will be important to ensure they are prepared swiftly
and that the details are sound.
The consequences of inadequate legislation in
these areas are not trivial. Clear and strictly
conditioned policies for non-therapeutic research and
the practice of clinical genetics are essential if we are to
improve care and outcome in these settings. Carefully
drafted legislation, underpinned by sensible guidance,
could facilitate research while addressing legitimate
public concerns.
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May be impractical unless diagnostic accuracy can be improved
Resistance of parasites to cheap, first line malariadrugs is a major obstacle to reducing the morethan one million deaths due to malaria each
year worldwide. Comparing the number of parasito-
logically confirmed cases of malaria with those that are
presumptively diagnosed reveals shockingly high rates
of overdiagnosis at peripheral and community levels
where self treatment is routine.1 If more expensive
drug treatments are introduced, this degree of
misdiagnosis of malaria cannot be condoned or
sustained.
Misdiagnosis of malaria in poorer countries
In sub-Saharan Africa more than 80% of individuals
with malaria self treat fevers with antimalarial drugs
without seeking help from the formal health sector.2
Sixty per cent of children with fever in Kenya, and 83%
in Togo, were treated at home with a malaria drug.3 4
Clinical signs alone are also used at primary healthcare
facilities, which lack laboratories for malaria diagnosis.
This approach is sensitive but not specific, so that in
areas with intermittent malaria transmission it is com-
mon for three quarters of febrile patients to be advised
to take antimalarials for a non-malarial illness.
Attempts to improve clinical diagnosis by using simple
algorithms have had only modest success.5 A combina-
tion of fever, splenomegaly, and pallor of the nailbed—
the best predictors for malaria parasitaemia in
Malawi—had 41% specificity, compared with a specifity
of 21% when fever alone was used.6
These high rates of misdiagnosis of malaria have
been tolerated because first line antimalarials are
relatively inexpensive and non-toxic. Misdiagnosis
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results in prolonged and worsening illness, reduced
productivity and school attendance, unnecessary
purchase of drugs and toxicity, and economic and
opportunity costs of clinic visits. At the population
level, overdiagnosis of malaria increases the perceived
levels of drug resistance (fever is unresponsive to
antimalarials) as well as real drug resistance (induced
by exposure of the parasite to subtherapeutic
concentrations of drugs).5
Higher drug costs should stimulate improvements
in diagnosis
Resistance to chloroquine, which costs $0.08 US
(£0.05; €0.07) per adult dose, is rapidly spreading
throughout Africa, and it has been replaced in several
countries in south eastern Africa by sulfadoxine-
pyrimethamine, which costs $0.12.7 Detection of resist-
ance to sulfadoxine-pyrimethamine is currently driv-
ing recommendations for newer, more expensive,
therapeutic strategies based on combinations of two
antimalarials (including artemisinin derivatives). The
rationale is that simultaneous use of two drugs with
different modes of action will inhibit the development
of resistance to either component. These combinations
cost between $1.12 (sulfadoxine-pyrimethamine plus
artesunate) and $3.90 (mefloquine plus artesunate) per
adult dose.8
Microscopic examination of a blood smear is the
gold standard method for the diagnosis of malaria.
Difficulties in servicing microscopes, training and
supervising technicians, and educating clinicians to use
results appropriately mean that microscopy is not usu-
ally available at subdistrict facilities, where the burden
of malaria is greatest.9 10 Rapid diagnostic tests based
on detection of malaria antigens are currently the only
feasible option for the field diagnosis of malaria. These
are dipsticks that provide a simple “present” or
“absent” result, usually represented as a coloured line,
on contact with blood and have been successfully used
in Colombia, Thailand,11 and Tanzania. Their wide-
spread use is restricted by cost and their inability to dif-
ferentiate clinically significant parasitaemia from the
low level asymptomatic parasitaemia that is common
in highly endemic areas.
Balancing the costs
Getting the balance right between investment in
accurate diagnosis and the cost of new drug regimens
will be influenced by the prevalence of malaria and pat-
terns of resistance, technical and clinical skills, and avail-
able resources. These vary widely between and even
within countries,making it difficult and inappropriate to
develop uniform international drug policies for malaria.
Is it reasonable to expect governments to make
rational decisions about investing in accurate diagnosis
of malaria without information about the overt and
hidden costs of incorrect diagnosis? To formulate
appropriate strategies, policy makers need information
on the cost effectiveness of various combinations of
diagnostic tools and treatment regimens. Calculation
of costs must not only include drugs and diagnostic
tests, but also the knock on effects of improving
diagnostic accuracy such as reductions in illness, death,
and drug resistance. In countries where malaria is still
susceptible to first line cheap drugs and the rate of
misdiagnosis is low an investment in accurate diagnosis
of malaria may be hard to justify. However, the diagno-
sis of malaria needs to be accurate in low transmission
zones where rates of overdiagnosis are high, single
agent treatments are failing, and more expensive com-
bination regimens are being considered.
The way forward
With increasing resistance to malaria, many resource
poor countries clearly will not be able to sustain the
current level of malaria misdiagnosis. The interna-
tional effort that is being put into developing new
malaria drugs should be paralleled by a commitment
to improve the availability of accurate diagnostic tools
for malaria, so that drugs can be targeted to people
with definite malarial illness. International agencies
have a key role in providing the evidence that govern-
ments need to make these decisions and to get appro-
priate evidence based diagnostic strategies for malaria
into practice.
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